News Releases

Date Title
03/28/18
Summary ToggleHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock Printer Friendly Version
03/28/18
Summary ToggleHeron Therapeutics Announces Proposed Public Offering of Common Stock Printer Friendly Version
03/21/18
Summary ToggleHeron Therapeutics to Present at the 17th Annual Needham Healthcare Conference Printer Friendly Version
03/19/18
Summary ToggleHeron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair Printer Friendly Version
03/06/18
Summary ToggleHeron Therapeutics to Present at the 38th Annual Cowen Healthcare Conference Printer Friendly Version
02/27/18
Summary ToggleHeron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress Printer Friendly Version
02/12/18
Summary ToggleHeron Therapeutics to Present at the 7th Annual Leerink Partners Global Healthcare Conference Printer Friendly Version
01/08/18
Summary ToggleHeron Therapeutics Highlights Progress in CINV and Pain Management Franchises Printer Friendly Version
01/02/18
Summary ToggleHeron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Printer Friendly Version
12/05/17
Summary ToggleHeron Therapeutics Announces Pricing of Public Offering of Common Stock Printer Friendly Version
12/04/17
Summary ToggleHeron Therapeutics Announces Public Offering of Common Stock Printer Friendly Version
11/09/17
Summary ToggleHeron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Printer Friendly Version
11/08/17
Summary ToggleHeron Therapeutics to Present at the Jefferies London Healthcare Conference Printer Friendly Version
11/06/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress Printer Friendly Version
10/26/17
Summary ToggleHeron Therapeutics Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain and the Need for Opioid Analgesics for 72 Hours Printer Friendly Version
09/18/17
Summary ToggleHeron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Printer Friendly Version
08/09/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress Printer Friendly Version
08/09/17
Summary ToggleHeron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA Printer Friendly Version
05/30/17
Summary ToggleHeron Therapeutics to Present at the Jefferies 2017 Healthcare Conference Printer Friendly Version
05/10/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress Printer Friendly Version
05/09/17
Summary ToggleHeron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference Printer Friendly Version
04/24/17
Summary ToggleHeron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance Printer Friendly Version
03/28/17
Summary ToggleHeron Therapeutics to Present at the 16th Annual Needham Healthcare Conference Printer Friendly Version
03/13/17
Summary ToggleHeron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference Printer Friendly Version
02/28/17
Summary ToggleHeron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference Printer Friendly Version
02/24/17
Summary ToggleHeron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines Printer Friendly Version
02/23/17
Summary ToggleHeron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress Printer Friendly Version
02/08/17
Summary ToggleHeron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference Printer Friendly Version
01/31/17
Summary ToggleHeron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares Printer Friendly Version
01/19/17
Summary ToggleHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock Printer Friendly Version
01/18/17
Summary ToggleHeron Therapeutics Announces Proposed Public Offering of Common Stock Printer Friendly Version
01/12/17
Summary ToggleHeron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Printer Friendly Version
01/05/17
Summary ToggleHeron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Printer Friendly Version
01/04/17
Summary ToggleHeron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies Printer Friendly Version
01/04/17
Summary ToggleHeron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty Printer Friendly Version
11/29/16
Summary ToggleSusan G. Komen® Joins Forces With Heron Therapeutics to Raise Awareness of the Supportive Care Needs of Patients With Breast Cancer Printer Friendly Version
11/08/16
Summary ToggleHeron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress Printer Friendly Version
09/08/16
Summary ToggleHeron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016 Printer Friendly Version
08/29/16
Summary ToggleHeron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016 Printer Friendly Version
08/10/16
Summary ToggleHeron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
08/08/16
Summary ToggleHeron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate Progress Printer Friendly Version
08/02/16
Summary ToggleHeron Therapeutics Enters into Loan Agreement for Up to $100 Million Printer Friendly Version
08/01/16
Summary ToggleHeron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain Printer Friendly Version
06/22/16
Summary ToggleHeron Therapeutics Announces Appointment of Christian Waage to Board of Directors Printer Friendly Version
06/15/16
Summary ToggleHeron Therapeutics to Present at the JMP Securities Life Sciences Conference Printer Friendly Version
05/05/16
Summary ToggleHeron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress Printer Friendly Version
04/18/16
Summary ToggleHeron Therapeutics Provides Update on FDA Review of SUSTOL® NDA Printer Friendly Version
03/17/16
Summary ToggleHeron Therapeutics Appoints David L. Szekeres, SVP Business Development, General Counsel and Corporate Secretary Printer Friendly Version
03/03/16
Summary ToggleHeron Therapeutics Provides Update on SUSTOL® NDA Printer Friendly Version
02/29/16
Summary ToggleHeron Therapeutics Provides Update on SUSTOL® NDA Printer Friendly Version
02/19/16
Summary ToggleHeron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress Printer Friendly Version
02/04/16
Summary ToggleHeron Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference Printer Friendly Version
01/28/16
Summary ToggleHeron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development Printer Friendly Version
01/15/16
Summary ToggleHeron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL® New Drug Application by the PDUFA Date Printer Friendly Version
11/10/15
Summary ToggleHeron Therapeutics to Participate in Investor Conferences in November 2015 Printer Friendly Version
11/06/15
Summary ToggleHeron Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Progress Printer Friendly Version
10/12/15
Summary ToggleHeron Therapeutics Appoints Neil J. Clendeninn, M.D., Ph.D. as Senior Vice President and Chief Medical Officer Printer Friendly Version
09/28/15
Summary ToggleHeron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL® at the ASCO Breast Cancer Symposium Printer Friendly Version
09/22/15
Summary ToggleHeron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Printer Friendly Version
09/22/15
Summary ToggleHeron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer Symposium Printer Friendly Version
09/18/15
Summary ToggleHeron Therapeutics Announces FDA Acceptance of New Drug Application for SUSTOL® Printer Friendly Version
08/07/15
Summary ToggleHeron Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Progress Printer Friendly Version
07/23/15
Summary ToggleHeron Therapeutics Initiates Second Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain Printer Friendly Version
07/20/15
Summary ToggleHeron Therapeutics Resubmits SUSTOL® New Drug Application to FDA Printer Friendly Version
06/16/15
Summary ToggleHeron Therapeutics Initiates Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain Printer Friendly Version
06/15/15
Summary ToggleHeron Therapeutics, Inc. Closes Underwritten Offering of Common Stock Printer Friendly Version
06/10/15
Summary ToggleHeron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock Printer Friendly Version
06/09/15
Summary ToggleHeron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common Stock Printer Friendly Version
05/28/15
Summary ToggleHeron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL® Printer Friendly Version
05/26/15
Summary ToggleHeron Therapeutics to Present at Investor Conferences in June 2015 Printer Friendly Version
05/14/15
Summary ToggleHeron Therapeutics Announces Positive Outcome from Meeting with FDA for HTX-019 Printer Friendly Version
05/08/15
Summary ToggleHeron Therapeutics Announces First Quarter 2015 Financial Results and Corporate Progress Printer Friendly Version
04/27/15
Summary ToggleHeron Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Printer Friendly Version
04/02/15
Summary ToggleHeron Therapeutics Reaches Target Patient Enrollment in MAGIC Phase 3 Study of SUSTOL® Printer Friendly Version
03/19/15
Summary ToggleHeron Therapeutics Reports Positive Results From Phase 1 Study of HTX-011 Printer Friendly Version
03/13/15
Summary ToggleHeron Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Progress Printer Friendly Version
02/23/15
Summary ToggleHeron Therapeutics to Present at Upcoming Healthcare Conferences Printer Friendly Version
02/11/15
Summary ToggleHeron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain Printer Friendly Version
02/03/15
Summary ToggleHeron Therapeutics to Present at the Leerink Partners 2015 Global Healthcare Conference Printer Friendly Version
12/02/14
Summary ToggleHeron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Printer Friendly Version
11/06/14
Summary ToggleHeron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV Printer Friendly Version
11/06/14
Summary ToggleHeron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights Printer Friendly Version
08/25/14
Summary ToggleHeron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and Secretary Printer Friendly Version
08/04/14
Summary ToggleHeron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results Printer Friendly Version
06/30/14
Summary ToggleHeron Therapeutics, Inc. Closes Underwritten Offering of Common Stock Printer Friendly Version
06/25/14
Summary ToggleHeron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock Printer Friendly Version
06/24/14
Summary ToggleHeron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common Stock Printer Friendly Version
06/20/14
Summary ToggleHeron Therapeutics Set to Join Russell 3000 Index Printer Friendly Version
06/12/14
Summary ToggleHeron Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference Printer Friendly Version
06/02/14
Summary ToggleHeron Therapeutics Provides Update on SUSTOL™ Program Printer Friendly Version
05/20/14
Summary ToggleHeron Therapeutics to Present at the Jefferies 2014 Global Health Care Conference Printer Friendly Version
05/19/14
Summary ToggleHeron Therapeutics Announces Data on SUSTOL™ Program to be Presented at 2014 ASCO Annual Meeting Printer Friendly Version
05/14/14
Summary ToggleHeron Therapeutics Reports Positive Results for Post-Surgical Pain Program Printer Friendly Version
05/08/14
Summary ToggleHeron Therapeutics Announces First Quarter 2014 Financial Results Printer Friendly Version
05/01/14
Summary ToggleHeron Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference Printer Friendly Version
03/31/14
Summary ToggleHeron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL™ Printer Friendly Version
03/05/14
Summary ToggleHeron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
01/27/14
Summary ToggleHeron Therapeutics Provides Update on Sustol Resubmission Printer Friendly Version
01/23/14
Summary ToggleHeron Therapeutics Announces Relisting on NASDAQ Printer Friendly Version
01/13/14
Summary ToggleA.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split Printer Friendly Version
11/25/13
Summary ToggleA.P. Pharma Closes Underwritten Offering of Common Stock Printer Friendly Version
11/20/13
Summary ToggleA.P. Pharma Announces Pricing of Underwritten Offering of Common Stock Printer Friendly Version
11/19/13
Summary ToggleA.P. Pharma Announces Proposed Underwritten Offering of Common Stock Printer Friendly Version
11/12/13
Summary ToggleA.P. Pharma Announces Pipeline Expansion Printer Friendly Version
11/12/13
Summary ToggleA.P. Pharma Announces Third Quarter 2013 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
11/04/13
Summary ToggleA.P. Pharma Makes Key Management Appointments Printer Friendly Version
08/08/13
Summary ToggleA.P. Pharma, Inc. Announces Planned Name Change to “Heron Therapeutics, Inc.” and Application to List on NASDAQ Capital Market Printer Friendly Version
08/08/13
Summary ToggleA.P. Pharma Announces Second Quarter 2013 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
07/08/13
Summary ToggleA.P. Pharma to Present at 8th Annual JMP Securities Healthcare Conference Printer Friendly Version
05/10/13
Summary ToggleA.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
05/02/13
Summary ToggleA.P. Pharma Appoints New Management Team Printer Friendly Version
03/28/13
Summary ToggleA.P. Pharma Receives FDA Complete Response Letter for APF530 Printer Friendly Version
03/01/13
Summary ToggleA.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
02/28/13
Summary ToggleA.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales Printer Friendly Version
12/17/12
Summary ToggleA.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530 Printer Friendly Version
12/13/12
Summary ToggleA.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer Printer Friendly Version
11/05/12
Summary ToggleA.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
10/18/12
Summary ToggleA.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer Printer Friendly Version
10/16/12
Summary ToggleA.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission Printer Friendly Version
09/28/12
Summary ToggleA.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
09/10/12
Summary ToggleA.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development Printer Friendly Version
08/02/12
Summary ToggleA.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress Printer Friendly Version
07/31/12
Summary ToggleA.P. Pharma Appoints Robert Rosen to Its Board of Directors Printer Friendly Version
07/25/12
Summary ToggleA.P. Pharma to Raise $53.6 Million in Common Stock Offering Printer Friendly Version
07/10/12
Summary ToggleA.P. Pharma Announces the Allowance of Three Patents Covering APF530 Printer Friendly Version
06/29/12
Summary ToggleA.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
06/21/12
Summary ToggleA.P. Pharma Appoints Barry Quart and Stephen Davis to Its Board of Directors Printer Friendly Version
06/20/12
Summary ToggleA.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study Printer Friendly Version
05/31/12
Summary ToggleA.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control Printer Friendly Version
05/10/12
Summary ToggleA.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate Progress Printer Friendly Version
03/26/12
Summary ToggleAPF530 Thorough QT Study Showed No Effect on Cardiac Repolarization Printer Friendly Version
03/26/12
Summary ToggleA.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530 Printer Friendly Version
03/26/12
Summary ToggleA.P. Pharma Appoints Thomas Ottoboni, Ph.D. as Vice President of Pharmaceutical Development Printer Friendly Version
01/06/12
Summary ToggleA.P. Pharma to Present at OneMedForum 2012 Financial Conference Printer Friendly Version
11/07/11
Summary ToggleA.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate Progress Printer Friendly Version
08/08/11
Summary ToggleA.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate Progress Printer Friendly Version
06/29/11
Summary ToggleA.P. Pharma to Raise $24 Million in Private Placement of Common Stock and Warrants Printer Friendly Version
05/16/11
Summary ToggleA.P. Pharma Announces First Quarter 2011 Financial Results and Recent Corporate Progress Printer Friendly Version
04/25/11
Summary ToggleA.P. Pharma Announces Financing of Up to $4.5 Million and Names CEO and COO Printer Friendly Version
04/25/11
Summary ToggleA.P. Pharma Provides Regulatory Update on APF530 NDA Printer Friendly Version
03/31/11
Summary ToggleA.P. Pharma Announces Transfer to OTCQB Printer Friendly Version
03/28/11
Summary ToggleA.P. Pharma Announces Fourth Quarter and Full Year 2010 Financial Results and Provides Corporate Update Printer Friendly Version
02/09/11
Summary ToggleA.P. Pharma Provides Update on APF530 Program and NASDAQ Listing Printer Friendly Version
11/22/10
Summary ToggleA.P. Pharma Receives Second Letter from NASDAQ Regarding Notice of Non-Compliance; Company to Request Hearing Printer Friendly Version
11/15/10
Summary ToggleA.P. Pharma Announces Third Quarter 2010 Financial Results Printer Friendly Version
08/16/10
Summary ToggleA.P. Pharma Announces Second Quarter 2010 Financial Results Printer Friendly Version
05/26/10
Summary ToggleA.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process Printer Friendly Version
05/20/10
Summary ToggleA.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule Printer Friendly Version
05/17/10
Summary ToggleA.P. Pharma Announces First Quarter 2010 Financial Results Printer Friendly Version
03/19/10
Summary ToggleA.P. Pharma Receives FDA Complete Response Letter for APF530 Printer Friendly Version
03/15/10
Summary ToggleA.P. Pharma Announces Fourth Quarter and Year-End 2009 Financial Results Printer Friendly Version
02/19/10
Summary ToggleA.P. Pharma Appoints Stephen R. Davis to Its Board of Directors Printer Friendly Version
01/11/10
Summary ToggleA.P. Pharma Receives $2.5 Million Milestone Payment Printer Friendly Version
01/11/10
Summary ToggleA.P. Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule Printer Friendly Version
11/23/09
Summary ToggleA.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements Printer Friendly Version
11/16/09
Summary ToggleA.P. Pharma Reports Third Quarter 2009 Financial Results Printer Friendly Version
10/28/09
Summary ToggleA.P. Pharma to Transfer to Nasdaq Capital Market Printer Friendly Version
10/20/09
Summary ToggleA.P. Pharma Announces Private Equity Placement Printer Friendly Version
09/21/09
Summary ToggleA.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule Printer Friendly Version
09/15/09
Summary ToggleA.P. Pharma and Merial Enter into Worldwide Agreement Printer Friendly Version
08/04/09
Summary ToggleA.P. Pharma Reports Second Quarter 2009 Financial Results Printer Friendly Version
07/20/09
Summary ToggleA.P. Pharma Receives Nasdaq Notice of Non-Compliance; Company to Request Hearing Printer Friendly Version
07/20/09
Summary ToggleA.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
06/03/09
Summary ToggleA.P. Pharma Receives Extension for Nasdaq Listing Compliance Printer Friendly Version
06/01/09
Summary ToggleA.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology Printer Friendly Version
05/29/09
Summary ToggleA.P. Pharma Announces Additional Restructuring Effort Printer Friendly Version
05/18/09
Summary ToggleA.P. Pharma Submits New Drug Application for APF530 in Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
05/18/09
Summary ToggleAPF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting Printer Friendly Version
05/14/09
Summary ToggleA.P. Pharma Reports First Quarter 2009 Financial Results Printer Friendly Version
04/07/09
Summary ToggleA.P. Pharma Receives Nasdaq Stockholder Equity Notification Printer Friendly Version
03/31/09
Summary ToggleA.P. Pharma Announces Fourth Quarter and Year-End 2008 Financial Results and Provides Update on APF530 NDA Printer Friendly Version
02/25/09
Summary ToggleA.P. Pharma Appoints John B. Whelan as Chief Financial Officer Printer Friendly Version
12/18/08
Summary ToggleA.P. Pharma Revises Target Date for APF530 NDA Printer Friendly Version
11/05/08
Summary ToggleA.P. Pharma Reports Results for the Third Quarter 2008 Printer Friendly Version
11/03/08
Summary ToggleA.P. Pharma to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12 Printer Friendly Version
10/29/08
Summary ToggleA.P. Pharma to Hold 2008 Third Quarter Financial Results Conference Call November 5 Printer Friendly Version
09/30/08
Summary ToggleA.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV Printer Friendly Version
09/29/08
Summary ToggleA.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern Printer Friendly Version
08/14/08
Summary ToggleA.P. Pharma Reports Results for the Second Quarter 2008 Printer Friendly Version
07/31/08
Summary ToggleA.P. Pharma to Hold 2008 Second Quarter Financial Results Conference Call August 14 Printer Friendly Version
07/09/08
Summary ToggleA.P. Pharma Announces Stock Option Grant Printer Friendly Version
07/07/08
Summary ToggleA.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of Directors Printer Friendly Version
06/23/08
Summary ToggleA.P. Pharma Completes Enrollment in Phase 3 Trial of APF530 Printer Friendly Version
05/15/08
Summary ToggleA.P. Pharma Reports Results for the First Quarter 2008 Printer Friendly Version
05/12/08
Summary ToggleA.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15 Printer Friendly Version
03/31/08
Summary ToggleA.P. Pharma Announces Stock Option Grants Printer Friendly Version
03/13/08
Summary ToggleA.P. Pharma Reports Results for the Fourth Quarter and Full Year 2007 Printer Friendly Version
03/10/08
Summary ToggleA.P. Pharma to Hold 2007 Fourth Quarter Financial Results Conference Call March 13 Printer Friendly Version
01/16/08
Summary ToggleA.P. Pharma Announces Stock Option Grant Printer Friendly Version
01/14/08
Summary ToggleA.P. Pharma Announces Executive Officer Departure Printer Friendly Version
01/02/08
Summary ToggleDutton Associates Announces Investment Opinion: A.P. Pharma Rated Strong Speculative Buy in Update Report by Dutton Associates Printer Friendly Version
12/21/07
Summary ToggleA.P. Pharma Announces Chief Executive Officer Succession Plan Printer Friendly Version
12/14/07
Summary ToggleA.P. Pharma Stockholders Approve 2007 Equity Incentive Plan and Amendment to 1997 Employee Stock Purchase Plan Printer Friendly Version
11/13/07
Summary ToggleA.P. Pharma Reports Third Quarter Financial Results Printer Friendly Version
11/08/07
Summary ToggleA.P. Pharma to Hold 2007 Third Quarter Financial Results Conference Call November 13 Printer Friendly Version
09/10/07
Summary ToggleA.P. Pharma to Present at Merriman Curhan Ford's Annual Investor Summit on September 17 Printer Friendly Version
08/01/07
Summary ToggleA.P. Pharma Reports Second Quarter Financial Results Printer Friendly Version
07/25/07
Summary ToggleA.P. Pharma to Hold 2007 Second Quarter Financial Results Conference Call August 1 Printer Friendly Version
06/25/07
Summary ToggleA.P. Pharma Regains Compliance with NASDAQ Global Market Listing Requirements Printer Friendly Version
06/19/07
Summary ToggleA.P. Pharma Closes $40 Million Common Stock Offering; Underwriters Exercise Full over-Allotment Option Printer Friendly Version
06/14/07
Summary ToggleA.P. Pharma Prices $35 Million Common Stock Offering Printer Friendly Version
06/07/07
Summary ToggleA.P. Pharma Receives $2.5 Million Milestone Payment Printer Friendly Version
05/24/07
Summary ToggleA.P. Pharma Clarifies Effective Date of Reverse Stock Split Printer Friendly Version
05/23/07
Summary ToggleA.P. Pharma Stockholders Approve Reverse Stock Split Printer Friendly Version
05/15/07
Summary ToggleA.P. Pharma Reports Receipt of Notice From NASDAQ Printer Friendly Version
05/08/07
Summary ToggleA.P. Pharma Reports Results for the First Quarter 2007 Printer Friendly Version
05/01/07
Summary ToggleA.P. Pharma to Hold 2007 First Quarter Financial Results Conference Call May 8 Printer Friendly Version
04/05/07
Summary ToggleA.P. Pharma Files Registration Statement for a Common Stock Offering Printer Friendly Version
04/05/07
Summary ToggleA.P. Pharma's 10-K Report Audit Includes 'Going-Concern' Qualification Printer Friendly Version
03/07/07
Summary ToggleA.P. Pharma Reports Results for the Fourth Quarter and Full Year 2006; Reports on Progress of APF530 Program Printer Friendly Version
02/28/07
Summary ToggleA.P. Pharma to Hold 2006 Fourth Quarter Financial Results Conference Call March 7 Printer Friendly Version
01/10/07
Summary ToggleDutton Associates Announces Investment Opinion: AP Pharma Strong Speculative Buy In Update By Dutton Associates Printer Friendly Version
12/21/06
Summary ToggleA.P. Pharma Resets APF530 NDA Filing Expectations Printer Friendly Version
11/20/06
Summary ToggleA.P. Pharma Names New Vice President of Clinical Development Printer Friendly Version
11/07/06
Summary ToggleA.P. Pharma Reports 2006 Third Quarter Results Printer Friendly Version
10/31/06
Summary ToggleA.P. Pharma to Hold 2006 Third Quarter Financial Results Conference Call November 7 Printer Friendly Version
10/02/06
Summary ToggleA.P. Pharma Licenses APF530 to RHEI Pharmaceuticals for Development in Greater China Printer Friendly Version
09/28/06
Summary ToggleA.P. Pharma Expects Data from APF530 Pivotal Trial in Second Half of 2007 Printer Friendly Version
09/12/06
Summary ToggleA.P. Pharma to Present at Merriman Curhan Ford ''Investor Summit 2006'' on September 18 Printer Friendly Version
08/14/06
Summary ToggleA.P. Pharma Names Arthur Taylor to Board of Directors Printer Friendly Version
08/08/06
Summary ToggleA.P. Pharma Reports 2006 Second Quarter Results; Phase 3 Clinical Trial for APF530 Underway Printer Friendly Version
07/28/06
Summary ToggleA.P. Pharma to Hold 2006 Second Quarter Financial Results Conference Call August 8 Printer Friendly Version
06/27/06
Summary ToggleDutton Associates Announces Investment Opinion: A.P. Pharma Maintained At Strong Speculative Buy Rating By Dutton Associates Printer Friendly Version
05/10/06
Summary ToggleA.P. Pharma Reports 2006 First Quarter Results; Phase 3 Clinical Trial for APF530 Initiated Printer Friendly Version
04/27/06
Summary ToggleA.P. Pharma Initiates APF530 Phase 3 Clinical Trial; IRB Approval Received Printer Friendly Version
03/15/06
Summary ToggleA.P. Pharma Reports 2005 Full Year and Fourth Quarter Results; APF530 Phase 3 Clinical Trial Planning at Advanced Stage, Patient Enrollment Expected to Begin in April Printer Friendly Version
03/09/06
Summary ToggleA.P. Pharma to Hold 2005 Fourth Quarter Financial Results Conference Call March 15 Printer Friendly Version
02/08/06
Summary ToggleDutton Associates Announces Investment Opinion: A.P. Pharma Inc. Strong Speculative Buy Rating and $3.00 Price Target Reiterated in Update by Dutton Associates Printer Friendly Version
01/24/06
Summary ToggleA.P. Pharma Announces Submission of APF530 Pivotal Trial Protocol for FDA Review; Phase 3 Trial to Compare APF530 With Palonosetron Printer Friendly Version
01/18/06
Summary ToggleA.P. Pharma Regains Compliance with NASDAQ National Market Listing Requirements; NASDAQ Believes Company in Compliance Based on Royalty Interest Sale Printer Friendly Version
01/18/06
Summary ToggleA.P. Pharma Completes Financing for up to $30 Million; Sells Royalty Rights to Retin-A Micro and Carac; Transaction is Non-Dilutive to Shareholders Printer Friendly Version
11/16/05
Summary ToggleA.P. Pharma Reports Receipt of Notice from NASDAQ Printer Friendly Version
11/04/05
Summary ToggleDutton Associates Announces Investment Opinion: A.P. Pharma Raised to Strong Speculative Buy Rating in Update by Dutton Associates Printer Friendly Version
11/03/05
Summary ToggleA.P. Pharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference Printer Friendly Version
11/02/05
Summary ToggleA.P. Pharma Reports Third Quarter Results; Preparations Underway for Pivotal Clinical Trials with APF530 Printer Friendly Version
10/26/05
Summary ToggleA.P. Pharma to Hold 2005 Third Quarter Financial Results Conference Call November 2 Printer Friendly Version
10/04/05
Summary ToggleA.P. Pharma to Hold APF530 Phase 2 Results Conference Call Today at 11:00 a.m. Eastern Time Printer Friendly Version
09/29/05
Summary ToggleA.P. Pharma Reports All Clinical Endpoints Achieved in APF530 Phase 2 Trial; Conference Call to Begin at 11:00 A.M. Eastern Time Tuesday, October 4, 2005 Printer Friendly Version
08/08/05
Summary ToggleA.P. Pharma Reports Second Quarter Financial Results; Patient Enrollment for APF530 Phase 2 Trial Successfully Completed Printer Friendly Version
07/29/05
Summary ToggleA.P. Pharma to Hold 2005 Second Quarter Financial Results Conference Call August 8 Printer Friendly Version
05/10/05
Summary ToggleA.P. Pharma Reports 2005 First Quarter Results; Cancer Patients Enrolled in Phase 2 Clinical Program for APF530 Printer Friendly Version
05/03/05
Summary ToggleA.P. Pharma to Hold 2005 First Quarter Financial Results Conference Call May 10 Printer Friendly Version
04/28/05
Summary ToggleA.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients Printer Friendly Version
04/01/05
Summary ToggleDutton & Associates Announces Investment Opinion: A.P. Pharma, Inc. Speculative Buy Rating in Update by Dutton Associates Printer Friendly Version
03/10/05
Summary ToggleA.P. Pharma Reports 2004 Fourth Quarter and Full Year Results; IND Submitted for APF530; Phase 2 Study Cleared to Begin in 2Q05 Printer Friendly Version
03/03/05
Summary ToggleA.P. Pharma to Hold 2004 Fourth Quarter & Year-End Financial Results Conference Call March 10 Printer Friendly Version
11/15/04
Summary ToggleA.P. Pharma Reports Third Quarter Financial Results; APF530 Phase 1 Study Successfully Completed Printer Friendly Version
11/05/04
Summary ToggleA.P. Pharma to Hold 2004 Third Quarter Financial Results Conference Call November 15 Printer Friendly Version
09/17/04
Summary ToggleA.P. Pharma to Hold Clinical and Business Update Conference Call September 21; Company to Discuss Development Plans for APF112 and APF530 Printer Friendly Version
08/12/04
Summary ToggleA.P. Pharma Reports Second Quarter Financial Results Printer Friendly Version
08/12/04
Summary ToggleA.P. Pharma Reports Preliminary Clinical Data Results from Studies Using APF112 AND APF530; Conference Call to Begin Today at 12:00 Noon ET/9:00 a.m. PT Printer Friendly Version
08/12/04
Summary ToggleA.P. Pharma to Hold Conference Call at 12 Noon Eastern Time Today to Discuss APF112 and APF530 Preliminary Trial Results, Second Quarter Financials Printer Friendly Version
08/06/04
Summary ToggleA.P. Pharma to Hold 2004 Second Quarter Financial Results Conference Call August 16; Company to Report APF112 and APF530 Preliminary Trial Results Printer Friendly Version
06/24/04
Summary ToggleA.P. Pharma Completes Common Stock Sale Printer Friendly Version
05/05/04
Summary ToggleA.P. Pharma Files Shelf Registration Statement Printer Friendly Version
04/28/04
Summary ToggleA.P. Pharma Reports First Quarter Results; Human Clinical Trials Underway with Two Product Candidates Printer Friendly Version
04/21/04
Summary ToggleA.P. Pharma to Hold 2004 First Quarter Financial Results Conference Call April 28 Printer Friendly Version
04/16/04
Summary ToggleA.P. Pharma Initiates Phase I Clinical Trial with APF530, a Potential Treatment for Chemotherapy-Induced Nausea and Vomiting Printer Friendly Version
03/12/04
Summary ToggleA.P. Pharma Reports 2003 Fourth Quarter and Full Year Results; Reports Results of Open-Label APF112 Phase 2 study Printer Friendly Version
03/04/04
Summary ToggleA.P. Pharma to Hold 2003 Fourth Quarter and Full-Year Financial Results Conference Call March 12 Printer Friendly Version
02/24/04
Summary ToggleStudy Indicates A.P. Pharma Polymer System Could Advance Clinical Utility of DNA Vaccines Against Cancer and Viral Infections; Data Published in Nature Materials Printer Friendly Version
01/26/04
Summary ToggleA.P. Pharma Provides APF112 Clinical Development Update; Phase II Data Expected by Mid-Year Printer Friendly Version
11/07/03
Summary ToggleA.P. Pharma Reports Third Quarter Results; APF112 Phase II Clinical Trial Initiated; Royalty Income Increases 23% Over Q3 2002 Printer Friendly Version
10/30/03
Summary ToggleA.P. Pharma to Hold Third Quarter Conference Call November 7, 2003 Printer Friendly Version
09/17/03
Summary ToggleA.P. Pharma Receives Additional Patent for 5-FU Microsponge Formulation; Patent Covering Carac Formulation Extended to 2021 Printer Friendly Version
08/26/03
Summary ToggleA.P. Pharma Ready to Initiate Phase II Studies With APF112; Company Plans to Initiate Phase II Clinical Trials in September Printer Friendly Version
08/04/03
Summary ToggleA.P. Pharma Reports Second Quarter Results; APF112 Phase II Clinical Package Submitted for FDA Review; Royalty Income Increases 11% Over 2Q 2002 Printer Friendly Version
07/24/03
Summary ToggleA.P. Pharma to Hold Second Quarter Conference Call August 4, 2003 Printer Friendly Version
05/05/03
Summary ToggleA.P. Pharma Reports First Quarter Results; Royalty Income Increases by 14% Over Q1 2002 Printer Friendly Version
04/28/03
Summary ToggleA.P. Pharma to Hold First Quarter Conference Call May 5, 2003 Printer Friendly Version
02/27/03
Summary ToggleA.P. Pharma Reports Fourth Quarter and Year-End 2002 Results Printer Friendly Version
02/21/03
Summary ToggleA.P. Pharma to Hold Fourth Quarter Conference Call February 27, 2003 Printer Friendly Version
02/14/03
Summary ToggleA.P. Pharma Sells Non-Core Business for Cash and Royalties Printer Friendly Version
12/11/02
Summary ToggleA.P. Pharma Names Robert L. Zerbe, M.D. To Board of Directors; New Member Brings To Board Additional Expertise in Regulatory Affairs and Clinical Development Printer Friendly Version
12/03/02
Summary ToggleA.P. Pharma Establishes Timetable to Re-Initiate Clinical Program for APF112; Company provides regulatory update on progress towards Phase II clinical studies Printer Friendly Version
11/21/02
Summary ToggleA.P. Pharma Inc. CEO Michael O'Connell Talks to the Wall Street Transcript Printer Friendly Version
11/07/02
Summary ToggleA.P. Pharma Reports Third Quarter Financial Results; Third Quarter Royalty Income Increases 30% Printer Friendly Version
10/31/02
Summary ToggleA.P. Pharma to Hold Third Quarter Conference Call November 7, 2002 Printer Friendly Version
08/16/02
Summary ToggleA.P. Pharma to Conduct Additional Preclinical Testing With APF112; Company Withdraws Proposed Phase II Protocol Printer Friendly Version
08/05/02
Summary ToggleA.P. Pharma Reports Second Quarter Financial Results; Royalty Income Continues to Increase; Clinical Programs Advance with Additional Corporate Collaborators Printer Friendly Version
07/29/02
Summary ToggleA.P. Pharma to Hold Second Quarter Conference Call August 5, 2002 Printer Friendly Version
05/15/02
Summary ToggleSecond Formulation of RETIN-A MICRO Approved for U.S. Market; Launch Anticipated in June 2002; Potential to Significantly Increase A.P. Pharma's Royalties Printer Friendly Version
05/07/02
Summary ToggleA.P. Pharma Reports First Quarter Results; Clinical Program for APF112 Initiated in 2002; Royalty Income Up 39% Over First Quarter 2001 Printer Friendly Version
05/01/02
Summary ToggleA.P. Pharma to Hold First Quarter Conference Call May 7, 2002 Printer Friendly Version
03/05/02
Summary ToggleA.P. Pharma Reports Fourth Quarter and Year-End 2001 Results; Substantial Progress for the Biochronomer Drug Delivery System in 2001 Printer Friendly Version
02/26/02
Summary ToggleA.P. Pharma To Hold Fourth Quarter Conference Call March 5, 2002 Printer Friendly Version
01/29/02
Summary ToggleA.P. Pharma Reports Initiation of Clinical Program for APF112; First Clinical Study Fully Enrolled Printer Friendly Version
12/20/01
Summary ToggleA.P. Pharma Files First Investigational New Drug Application for APF112 Formulation Using Biochronomer System Printer Friendly Version
11/06/01
Summary ToggleA.P. Pharma Reports Third Quarter 2001 Results; Carac Achieves 26% Topical Market Share in Second Quarter after Launch Printer Friendly Version
10/31/01
Summary ToggleA.P. Pharma to Hold Third Quarter 2001 Conference Call Nov. 6, 2001 Printer Friendly Version
09/26/01
Summary ToggleSecond New Drug Application Filed for Retin-A Micro; Potential to Significantly Increase A.P. Pharma's Royalties Printer Friendly Version
08/07/01
Summary ToggleA.P. Pharma Reports Second Quarter 2001 Results; Royalty Income Increases, Proprietary Product-Development Programs Underway Printer Friendly Version
07/23/01
Summary ToggleRetin-A Micro Receives Marketing Clearance in Canada; Johnson & Johnson Canada to Market Prescription Acne Treatment Containing Microsponge Systems in Canada Printer Friendly Version
06/26/01
Summary ToggleA.P. Pharma Successfully Completes Pre-Clinical Safety Evaluations Of Biochronomer™ System Printer Friendly Version
06/01/01
Summary ToggleA.P. Pharma To Present At Wall Street Analyst Forum, June 7 Printer Friendly Version
05/30/01
Summary ToggleA.P. Pharma Appoints Vice President Of Business Development Printer Friendly Version
05/14/01
Summary ToggleAdvanced Polymer Systems Changes Name To A.P. Pharma Printer Friendly Version
05/03/01
Summary ToggleAdvanced Polymer Systems Reports First Quarter 2001 Results Printer Friendly Version
04/12/01
Summary ToggleAdvanced Polymer Systems To Begin Receiving Royalties From Sales Of Dermik’s Carac™ For Treatment Of Actinic Keratoses Printer Friendly Version
03/13/01
Summary ToggleAdvanced Polymer Systems Reports Fourth Quarter And Full-Year 2000 Results Printer Friendly Version
11/01/00
Summary ToggleAdvanced Polymer Systems Appoints Experienced Pharmaceutical Industry Executive As Chairman Printer Friendly Version
10/30/00
Summary ToggleFDA Grants Marketing Clearance For New Formulation Printer Friendly Version
08/02/00
Summary ToggleAdvanced Polymer Systems Announces Key Management Changes Printer Friendly Version
07/26/00
Summary ToggleAdvanced Polymer Systems Completes Sale Of Cosmeceutical Product Lines And Technology Rights For Certain Topical Pharmaceuticals To R.P. Scherer Printer Friendly Version